Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia and myasthenic syndrome of various etiologies. Diseases of the central nervous system (CNS): bulbar paralysis and paresis; recovery period of organic lesions of the CNS, which are accompanied by motor disorders.
active substance: ipidacrine hydrochloride;
Neuromidin 15 mg / ml solution for injection: 1 ml solution for injection (one ampoule) contains 15 mg ipidacrine hydrochloride in terms of anhydrous substance;
Excipients: water for injections.
Solution for injection.
Neuromidin is a reversible cholinesterase inhibitor.
Neuromidin has a direct stimulating effect on the conduction of impulses through nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous systems.
Pharmacological action Neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels in the membrane of neurons and muscle cells;
reversible inhibition of cholinesterase at synapses.
Neuromidin enhances the smooth muscle effects of not only acetylcholine but also adrenaline, serotonin, histamine and oxytocin.
Neuromidin exhibits the following decisive pharmacological effects:
- restores and stimulates the conduction of impulses in the nervous system and neuromuscular transmission;
- enhances the contractility of smooth muscle organs under the influence of all antagonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except for potassium chloride;
- improves memory, inhibits the progressive development of dementia;
- restores the conduction of impulses in the peripheral nervous system, disrupted by various factors such as trauma, inflammation, local anesthetics, some antibiotics, potassium chloride, toxins, etc .;
- moderately stimulates the central nervous system in combination with the manifestations of certain sedative effects;
- exhibits analgesic effect;
- exhibits antiarrhythmic effect.
The drug has no teratogenic, embryotoxic, mutagenic and carcinogenic, as well as allergenic and immunotoxic effects, and does not affect the endocrine system.
Indications for use:
- Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia and myasthenic syndrome of various etiologies.
- Diseases of the central nervous system (CNS): bulbar paralysis and paresis; recovery period of organic lesions of the CNS, which are accompanied by motor disorders.
- Hypersensitivity to ipidacrine.
- Extrapyramidal disorders with hyperkinesis.
- Angina pectoris.
- Severe bradycardia.
- Bronchial asthma.
- Vestibular disorders.
- Mechanical obstruction of the intestines and urinary tract.
- Gastric ulcer or duodenal ulcer in the acute stage.
There are no systematic data on the use of the parenteral form of the drug Neuromidine in children (under 18 years of age), so the drug should not be used in children.
Use during pregnancy or breastfeeding
Neuromidin increases the tone of the uterus and can cause premature birth, so the use of the drug during pregnancy is contraindicated.
During breastfeeding, the drug is contraindicated.
Method of application and dosage
The solution for injection should be given intramuscularly or subcutaneously. The dose and duration of treatment should be determined individually depending on the severity of the disease.
Diseases of the peripheral nervous system:
- Mono- and polyneuropathy of various genesis: subcutaneously or intramuscularly administered 5–15 mg 1-2 times a day, course of treatment 10–15 days (in severe cases up to 30 days); then treatment should be continued in tablet form.
- Myasthenia and myasthenic syndrome: subcutaneously or intramuscularly administered 5-30 mg 1-3 times a day, followed by switching to tablet form. The general course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.
- Diseases of the central nervous system: bulbar paralysis and paresis: subcutaneously and intramuscularly 5-15 mg 1-2 times a day, the course of treatment – 10-15 days, if possible, switch to tablet form.
- Recovery period for organic lesions of the CNS: intramuscularly 10-15 mg 1-2 times a day, a course of treatment up to 15 days, then if possible 1-2 times a day.
Symptoms. In severe overdose may develop a “cholinergic crisis”, which is characterized by:
bronchospasm, lacrimation, increased sweating, narrowing of the pupils, nystagmus, increased perilstatics of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, decreased blood pressure, blood pressure, atauria , convulsions, coma, speech disorders, drowsiness, general weakness.
Treatment: symptomatic therapy should be used, m-cholinoblockers should be used: atropine, cyclodol, metacin, etc.
- Cardiac disorders: increased heart rate, bradycardia.
- Nervous system disorders: dizziness, headache, drowsiness (at high doses).
- Disorders of the respiratory tract, chest and mediastinum: increased secretion of bronchi, bronchospasm.
- Disorders of the gastrointestinal tract: increased salivation, nausea; when using high doses – vomiting, diarrhea, epigastric pain.
- Liver disorders: jaundice.
- Skin and subcutaneous tissue disorders: increased sweating; allergic reactions, including rash, pruritus, urticaria, angioneurotic edema.
- Disorders of the reproductive system: increased uterine tone.
- Musculoskeletal and connective tissue disorders: muscle cramps (at high doses).
- Immune system disorders: hypersensitivity reactions (including allergic dermatitis, anaphylactic shock, asthma, toxic epidermal necrolysis, erythema, urticaria, wheezing, laryngeal edema, injection site rash).
- General disorders and administration site conditions: weakness (at high doses).
Store in the original package at a temperature not exceeding 25 ° C.
Keep out of reach of children.